The availability of two proprotein convertase subtilisin-like kexin type 9 (PCSK9) monoclonal antibody therapies, alirocumab and evolocumab to treat dyslipidemia in persons with ASCVD or familial hypercholesterolemia requiring additional LDL-C reduction despite optimization of lifestyle changes and maximally tolerated statin therapy, has revolutionized the landscape for treatment of dyslipidemia (3). This evidence concerns the gene PCSK9 and metabolic syndrome.